Popular Trials
Mu-opioid Receptor Agonist
Eluxadoline for Irritable Bowel Syndrome
This trial is testing a medication to help manage IBS-D symptoms in children. The goal is to see how well it works, how the body processes it, and if it is safe for kids. The study focuses on children because they need effective treatments for IBS-D. The medication is taken orally and is designed to treat diarrhoea-predominant irritable bowel syndrome.
Popular Filters
Trials for IBS Patients
Behavioural Intervention
Fecal Microbiota Transplantation for Depression
This trial is testing whether a treatment called Fecal Microbiota Transplantation (FMT) is effective, safe, and tolerable for adults with Major Depressive Disorder (MDD) who also have Inflammatory Bowel Syndrome (IBS). The study will also look at whether FMT affects cognitive and neural changes associated with MDD and MDD+IBS.
Behavioural Intervention
Mindfulness Training for Irritable Bowel Syndrome
This trial will compare the effectiveness of two different mindfulness-based interventions (MBIs) for treating irritable bowel syndrome (IBS), with a control group who will receive stress management training. The trial will use both clinician and patient assessed measures of IBS symptoms, as well asEcological Momentary Assessment to assess stress and symptoms in daily life.
Mu-opioid Receptor Agonist
Eluxadoline for Pediatric IBS-D
This trial will check the safety of a medication called Eluxadoline for children with IBS-D who have already taken part in earlier studies. The medication helps to reduce diarrhea and stomach pain by slowing down bowel movements. Eluxadoline is a new drug approved for managing diarrhea predominant irritable bowel syndrome (IBS-D).
Phase 3 Trials
Behavioural Intervention
Fecal Microbiota Transplantation for Depression
This trial is testing whether a treatment called Fecal Microbiota Transplantation (FMT) is effective, safe, and tolerable for adults with Major Depressive Disorder (MDD) who also have Inflammatory Bowel Syndrome (IBS). The study will also look at whether FMT affects cognitive and neural changes associated with MDD and MDD+IBS.
Mu-opioid Receptor Agonist
Eluxadoline for Pediatric IBS-D
This trial will check the safety of a medication called Eluxadoline for children with IBS-D who have already taken part in earlier studies. The medication helps to reduce diarrhea and stomach pain by slowing down bowel movements. Eluxadoline is a new drug approved for managing diarrhea predominant irritable bowel syndrome (IBS-D).
Behavioural Intervention
TEA + Lexapro for Irritable Bowel Syndrome
This trial tests TEA and escitalopram on people with IBS-C to see if they can reduce abdominal pain. TEA uses electrical currents on the skin, and escitalopram boosts serotonin in the brain.
Guanylate Cyclase-C Agonist
Long-Term Safety of Linaclotide for Constipation
This trial tests linaclotide, a medication that helps relieve constipation by increasing fluid in the intestines, in children aged 6-17 with constipation issues. Linaclotide is approved for treating certain types of constipation.
Trials With No Placebo
Behavioural Intervention
Fecal Microbiota Transplantation for Depression
This trial is testing whether a treatment called Fecal Microbiota Transplantation (FMT) is effective, safe, and tolerable for adults with Major Depressive Disorder (MDD) who also have Inflammatory Bowel Syndrome (IBS). The study will also look at whether FMT affects cognitive and neural changes associated with MDD and MDD+IBS.
Behavioural Intervention
Mindfulness Training for Irritable Bowel Syndrome
This trial will compare the effectiveness of two different mindfulness-based interventions (MBIs) for treating irritable bowel syndrome (IBS), with a control group who will receive stress management training. The trial will use both clinician and patient assessed measures of IBS symptoms, as well asEcological Momentary Assessment to assess stress and symptoms in daily life.
Mu-opioid Receptor Agonist
Eluxadoline for Pediatric IBS-D
This trial will check the safety of a medication called Eluxadoline for children with IBS-D who have already taken part in earlier studies. The medication helps to reduce diarrhea and stomach pain by slowing down bowel movements. Eluxadoline is a new drug approved for managing diarrhea predominant irritable bowel syndrome (IBS-D).
Non-invasive Brain Stimulation
Brain Stimulation for Gastrointestinal Disorders
This trial is testing a non-invasive brain stimulation technique called rTMS on healthy people and those with IBS or FD. The goal is to see if it can help regulate automatic body functions like digestion and heart rate by changing brain activity. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that has been used to treat various neurological and psychiatric conditions, including major depression, migraine-associated headaches, and obsessive-compulsive disorder.
View More Related Trials
Frequently Asked Questions
Introduction to irritable bowel syndrome
What are the top hospitals conducting irritable bowel syndrome research?
Seeking relief from the often-debilitating symptoms of irritable bowel syndrome (IBS) can be a challenging journey, but thanks to leading hospitals and research centers, progress is being made. In Ann Arbor, Michigan, the University of Michigan takes center stage in pioneering IBS clinical trials with six active studies dedicated to this complex condition. Since conducting their first trial in 2007, they have accumulated an impressive total of 13 investigations aimed at unraveling the mysteries surrounding IBS.
In sunny Miami at the Valencia Medical and Research Center, researchers are also committed to advancing our understanding of IBS. Though relatively new to the field compared to others on this list, they have already recorded three current trials and are building upon their initial foray into IBS research in 2017.
Heading westward to San Antonio's Sun Research Institute reveals another hub for groundbreaking studies related to IBS. With three ongoing trials and a respectable history of eight completed studies since initiating their very first trial back in 2006; it showcases that age-old saying "everything is bigger in Texas," extends even towards advancements in medical science.
Meanwhile, nestled within Los Angeles' prestigious UCLA lies a focus on two current clinical trials targeting IBS symptoms. Although they may seem modest in number compared to other institutions listed here; each undertaking contributes significantly towards expanding our knowledge on how best address these challenges faced by those living with this chronic condition since beginning later just recently alongside its counterpart during2017.
As we venture north across the border into Toronto's Canadian Phase Onward Inc., we encounter yet another institution dedicated not only improving patient outcomes but discovering innovative treatment options as well.With two active trials alongside four previous experiments exploring various facets affecting individuals grappling withIrritable Bowel Syndrome(I.B.S), together accumulating invaluable insights throughout all-time records tracing back till early2005
From coast-to-coast and beyond borders these top hospitals strive relentlessly identifying better ways manage IBS symptoms while delving into the underlying mechanisms of this condition. Through their relentless pursuit in clinical trials, they offer hope to those seeking relief and contribute to a future where living with IBS becomes more manageable for individuals worldwide.
Which are the best cities for irritable bowel syndrome clinical trials?
For irritable bowel syndrome clinical trials, several cities emerge as top contenders for research opportunities. Miami, Florida takes the lead with 21 active trials investigating treatments such as Eluxadoline and Linaclotide at varying dosages. Following closely behind is Houston, Texas with 11 ongoing studies focusing on interventions like 72 μg linaclotide and Eluxadoline. Atlanta, Georgia also shows promise in IBS research with 10 active trials examining similar treatment options. Ann Arbor, Michigan contributes to the field through eight ongoing trials studying interventions such as Rifaximin and specialized diets. Lastly, Stockbridge, Georgia offers seven active trials exploring potential treatments including Eluxadoline and Linaclotide across different dosages. These cities present individuals dealing with irritable bowel syndrome an opportunity to participate in cutting-edge clinical research that may pave the way for improved care outcomes in this condition.
Which are the top treatments for irritable bowel syndrome being explored in clinical trials?
Exciting developments are underway in the world of irritable bowel syndrome (IBS) treatments, with several options showing promise in clinical trials. Leading the way is rifaximin, currently being explored in two active trials dedicated to IBS. This powerful drug first entered the scene in 2007 and has since accumulated a total of 12 all-time clinical trials focused on this condition. Additionally, two different diets have emerged as potential therapies for IBS: Diet A and a diet low in all FODMAP groups. Both diets are each being investigated through one active trial, which marks their initial foray into research specifically targeting IBS. As these trials progress and results come to light, new avenues of relief may soon be available to individuals living with this challenging disorder.
What are the most recent clinical trials for irritable bowel syndrome?
Exciting advancements are being made in the field of irritable bowel syndrome (IBS) research, with recent clinical trials offering promising possibilities for improved treatment options. One notable trial involves the use of donor fecal microbiota transplantation (FMT) as a potential therapy for IBS. This Phase 2 study aims to investigate the effectiveness and safety of FMT in alleviating symptoms associated with this condition. Another noteworthy trial focuses on tenapanor, which is currently undergoing Phase 3 testing for its efficacy in managing IBS symptoms. Additionally, a Phase 3 trial exploring the effects of tenapanor at a specific dosage has also become available recently. With these compelling studies underway, there is renewed hope for individuals suffering from IBS to find relief and enhance their quality of life.
What irritable bowel syndrome clinical trials were recently completed?
Recently, three important clinical trials focusing on irritable bowel syndrome (IBS) have concluded, enhancing our understanding and treatment options for this complex condition. In December 2021, Michael Camilleri, MD completed a trial investigating the efficacy of Aldafermin. Cedars-Sinai Medical Center also wrapped up their own study in November 2020 on Rifaximin's potential benefits. Additionally, Beth Israel Deaconess Medical Center successfully concluded their DS-01 trial in October 2020. These significant advancements shed light on innovative approaches to managing IBS symptoms and offer hope for individuals grappling with this challenging gastrointestinal disorder.